{
      "Rank": 108,
      "Acronym": [
            "CELOPHIN"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Allogenic Adiposse derived mesenchimal stem cells (MSC) Dose: 12,5 million cells",
            "Allogenic Adiposse derived mesenchimal stem cells (MSC) Dose: 12,5 million cells at day 0 and 12,5 million cells at day 14"
      ],
      "ArmGroupInterventionName": [
            "Drug: Single Dose",
            "Drug: Double Dose"
      ],
      "ArmGroupLabel": [
            "Single dose Allogenic Adiposse derived mesenchimal stem cells",
            "Double dose Allogenic Adiposse derived mesenchimal stem cells"
      ],
      "ArmGroupType": [
            "Experimental",
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT05520086"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "A phase IIa, open label, non controlled clinical trial to assess the feasibility and safety of allogeneic adipose-derived mesenchymal stem cells (ASC) in the treatment of cicatricial conjunctivitis associated with Lyell's syndrome, Stevens-Johnson's syndrome and mucous membrane pemphigoid with ocular involvement"
      ],
      "BriefTitle": [
            "Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis."
      ],
      "CentralContactEMail": [
            "lucia.llanos@quironsalud.es",
            "eva.cerezo@quironsalud.es"
      ],
      "CentralContactName": [
            "Lucia Llanos",
            "Eva Cerezo"
      ],
      "CentralContactPhone": [
            "91 5504800",
            "91 5504800"
      ],
      "CentralContactPhoneExt": [
            "3245",
            "3214"
      ],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [
            "INDUSTRY"
      ],
      "CollaboratorName": [
            "Effice Servicios Para la Investigacion S.L."
      ],
      "CompletionDate": [
            "February 2024"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Chronic Conjunctivitis",
            "Stevens-Johnson Syndrome",
            "Lyell Syndrome",
            "Pemphigoid"
      ],
      "ConditionAncestorId": [
            "D000004194",
            "D000010335",
            "D000003229",
            "D000005128",
            "D000012872",
            "D000012871",
            "D000001327",
            "D000007154",
            "D000013280",
            "D000009059",
            "D000009057",
            "D000003875",
            "D000003872",
            "D000004892",
            "D000004890",
            "D000004342",
            "D000006967",
            "D000064420",
            "D000064419"
      ],
      "ConditionAncestorTerm": [
            "Disease",
            "Pathologic Processes",
            "Conjunctival Diseases",
            "Eye Diseases",
            "Skin Diseases, Vesiculobullous",
            "Skin Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases",
            "Stomatitis",
            "Mouth Diseases",
            "Stomatognathic Diseases",
            "Drug Eruptions",
            "Dermatitis",
            "Erythema Multiforme",
            "Erythema",
            "Drug Hypersensitivity",
            "Hypersensitivity",
            "Drug-Related Side Effects and Adverse Reactions",
            "Chemically-Induced Disorders"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All",
            "BC11",
            "BC07",
            "BC17",
            "BC20",
            "BC25",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions",
            "Eye Diseases",
            "Mouth and Tooth Diseases",
            "Skin and Connective Tissue Diseases",
            "Immune System Diseases",
            "Substance Related Disorders",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Syndrome",
            "Conjunctivitis",
            "Stevens-Johnson Syndrome",
            "Pemphigoid",
            "Pemphigoid",
            "Stevens-Johnson Syndrome"
      ],
      "ConditionBrowseLeafId": [
            "M15507",
            "M5607",
            "M15205",
            "M12454",
            "M5605",
            "M7423",
            "M14826",
            "M14827",
            "M3781",
            "M9352",
            "M15222",
            "M11171",
            "M11169",
            "M7371",
            "M6222",
            "M6219",
            "M7196",
            "M7198",
            "M9170",
            "M6669",
            "M29456",
            "M29455",
            "T1303",
            "T891",
            "T5478",
            "T2132"
      ],
      "ConditionBrowseLeafName": [
            "Syndrome",
            "Conjunctivitis",
            "Stevens-Johnson Syndrome",
            "Pemphigoid, Bullous",
            "Conjunctival Diseases",
            "Eye Diseases",
            "Skin Diseases",
            "Skin Diseases, Vesiculobullous",
            "Autoimmune Diseases",
            "Immune System Diseases",
            "Stomatitis",
            "Mouth Diseases",
            "Stomatognathic Diseases",
            "Exanthema",
            "Drug Eruptions",
            "Dermatitis",
            "Erythema",
            "Erythema Multiforme",
            "Hypersensitivity",
            "Drug Hypersensitivity",
            "Drug-Related Side Effects and Adverse Reactions",
            "Chemically-Induced Disorders",
            "Chronic Graft Versus Host Disease",
            "Bullous Pemphigoid",
            "Stevens-Johnson Syndrome/toxic Epidermal Necrolysis",
            "Erythema Multiforme"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "high",
            "low"
      ],
      "ConditionMeshId": [
            "D000013262",
            "D000003231",
            "D000010391",
            "D000013577"
      ],
      "ConditionMeshTerm": [
            "Stevens-Johnson Syndrome",
            "Conjunctivitis",
            "Pemphigoid, Bullous",
            "Syndrome"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Non-Randomized"
      ],
      "DesignInterventionModel": [
            "Sequential Assignment"
      ],
      "DesignInterventionModelDescription": [
            "2 consecutive cohorts will be included in order of recruitment. the first 10 patients will receive 1 single dose and the second 10 patients will receive 2 doses separated by 15 days"
      ],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "A multicentre, nationwide clinical trial will be performed. 20 patients fulfilling eligibility criteria will be included in two different dose level cohorts: the first 10 patients included will receive a single cell application and the remainder 10 will be administered 2 cell applications separated by 15 days.\n\nThe investigational drug consists of locally administered, expanded, allogeneic adipose-derived adult mesenchymal stem cells (ASCs), at a dose of 5 million cells per ml (0,5 ml to be infused per quadrant)\n\nStudy cronogram: recruitment is estimated to take 8 months, and follow-up period will be 12 months."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nMen and women over 18 years of age.\nDiagnosis of ocular pemphigoid in Foster stages I-IIcIIIb (2) or diagnosis of recurrent chronic or episodic inflammation accompanied by cicatricial conjunctivitis of the mucous membranes with ocular involvement after the acute phase of Stevens-Johnson Syndrome or Lyell Syndrome with insufficient disease control or inaceptable toxicity or impossibility to administer usual care treatments (according to physician or patient criteria)\nIn the case of women of childbearing age, who are willing to use an effective contraceptive method during the period of participation in the study\nConsent to participate and signature of the informed consent\n\nExclusion Criteria:\n\nSigns of active infection on the ocular surface.\nHistory of neoplasms in the last 5 years. except for epithelial basal or squamous cell carcinoma\nAllergy to local anesthetics\nPatients who have participated in another clinical trial with medication during the 90 days prior to signing the IC\nMedical or psychiatric illness of any kind that, in the opinion of the investigator, may be a reason for exclusion from the study.\nCongenital or acquired immunodeficiencies.\nMajor surgery or serious trauma of the subject in the semester prior to signing the IC.\nPregnant or lactating women.\nImpossibility or refusal to carry out the follow-up required in the study by the patient"
      ],
      "EnrollmentCount": [
            "20"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Single dose Allogenic Adiposse derived mesenchimal stem cells",
            "Double dose Allogenic Adiposse derived mesenchimal stem cells"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Single Dose: Administration of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection.",
            "Repetead Dose: Administration of 2 doses, separated by 14 days, of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection."
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Single Dose",
            "Double Dose"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "August 29, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "August 26, 2022"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Instituto de Investigaci\u00f3n Sanitaria de la Fundaci\u00f3n Jim\u00e9nez D\u00edaz"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Oviedo",
            "Barakaldo",
            "Alc\u00e1zar De San Juan",
            "C\u00f3rdoba",
            "Madrid",
            "Madrid",
            "Madrid",
            "Valladolid"
      ],
      "LocationContactEMail": [
            "merayo@fio.as",
            "jaime.echevarriaecenarro@osakidetza.eus",
            "celisalcazar@hotmail.com",
            "antoniocanoortiz@gmail.com",
            "nlferrando@telefonica.net",
            "nalejandre@quironsalud.es",
            "anam.botodelos@salud.madrid.org",
            "davidgalarreta@hotmail.com"
      ],
      "LocationContactName": [
            "Jes\u00fas Manuel Merayo Llov\u00e9s",
            "Jaime Echevarria Ecenarro",
            "Javier Celis S\u00e1nchez",
            "Antonio Cano Ortiz",
            "Nicol\u00e1s L\u00f3pez Ferrando",
            "Nicolas Alejandre Alba",
            "Ana Boto de los Bueis",
            "David Galarreta Mira"
      ],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact",
            "Contact"
      ],
      "LocationCountry": [
            "Spain",
            "Spain",
            "Spain",
            "Spain",
            "Spain",
            "Spain",
            "Spain",
            "Spain"
      ],
      "LocationFacility": [
            "Instituto Oftalmol\u00f3gico Fern\u00e1ndez - Vega",
            "Hospital Universitario de Cruces",
            "Hospital General La Mancha Centro",
            "Hospital La Arruzafa",
            "Hospital General Universitario Gregorio Mara\u00f1on",
            "Hospital Universitario Fundaci\u00f3n Jim\u00e9nez Diaz",
            "Hospital Universitario La Paz",
            "Hospital Cl\u00ednico Universitario de Valladolid"
      ],
      "LocationState": [
            "Asturias",
            "Bizkaia",
            "Ciudad Real"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "33012",
            "48903",
            "13600",
            "14012",
            "28007",
            "28040",
            "28046",
            "47003"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Phase IIa Multicenter Clinical Trial to Determine the Feasibility and Safety of the Use of Adipose-derived Mesenchymal Stem Cells (ASC) in the Treatment of Patients With Cicatricial Conjunctivitis Associated With Lyell's Syndrome, Stevens-Johnson Syndrome and Pemphigoid of the Mucous Membranes With Ocular Involvement."
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Instituto de Investigaci\u00f3n Sanitaria de la Fundaci\u00f3n Jim\u00e9nez D\u00edaz"
      ],
      "OrgStudyId": [
            "CELOPHIN"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Hospital Fundaci\u00f3n Jim\u00e9nez Diaz"
      ],
      "OverallOfficialName": [
            "Nicol\u00e1s Alejandre Alba"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Not yet recruiting"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "February 2024"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Percentage of complications related to anesthesia, administration of investigational medicinal product and postoperative period."
      ],
      "PrimaryOutcomeMeasure": [
            "Percentage of complications"
      ],
      "PrimaryOutcomeTimeFrame": [
            "Through study completion, an average of 3 years"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Changes from baseline in scarring conjunctivitis rating scale",
            "Changes from baseline in Ocular Surface Disease Index (OSDI) questionnaire (0-48). The lower the rate obtained in the score, better the outcome.",
            "Changes from baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) (0-1,2).\n\nThe higher the rate obtained in the score, better the outcome.",
            "Changes from baseline using the specific National Eye Institute-Visual Function Questionnaire 25 (NEI-VFQ-25) (0-100). The value of 0 is the lowest and 100 the best possible",
            "variation in the number and type of microorganisms in the conjunctival exudates, performing cultures and PCR herpes viridae"
      ],
      "SecondaryOutcomeMeasure": [
            "Signs improvement",
            "Symptom improvement",
            "Visual acuity improvement",
            "changes in quality of life",
            "evolution of the conjunctival flora"
      ],
      "SecondaryOutcomeTimeFrame": [
            "At 7 days (and 21 days in the 2-dose group), 4 weeks, 12 weeks, 24 weeks and 52 weeks",
            "At 7 days (and 21 days in the 2-dose group), 4 weeks, 12 weeks, 24 weeks and 52 weeks",
            "At 7 days (and 21 days in the 2-dose group), 4 weeks, 12 weeks, 24 weeks and 52 weeks",
            "At 7 days (and 21 days in the 2-dose group), 4 weeks, 12 weeks, 24 weeks and 52 weeks",
            "At 7 days (and 21 days in the 2-dose group), 4 weeks, 12 weeks, 24 weeks and 52 weeks"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "September 2022"
      ],
      "StartDateType": [
            "Anticipated"
      ],
      "StatusVerifiedDate": [
            "August 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "August 29, 2022"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "August 22, 2022"
      ],
      "StudyFirstSubmitQCDate": [
            "August 26, 2022"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}